Yimei Que

1095 Jie Fang Avenue
Wuhan, 430030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Letter to the Editor concerning: T2 mapping of the articular cartilage as a biomarker for knee osteoarthritis: An analysis of the population-based Rotterdam Study.

Letter to the Editor concerning: T2 mapping of the articular cartilage as a biomarker for knee osteoarthritis: An analysis of the population-based Rotterdam Study.

Journal: Osteoarthritis and cartilage

Published: October 13, 2025

XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.

XPO1 inhibition displays anti-leukemia efficacy against DNMT3A-mutant acute myeloid leukemia via downregulating glutathione pathway.

Journal: Annals of hematology

Published: January 18, 2024

Case report: Light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapy.

Case report: Light-chain amyloidosis responsive to selinexor in combination with daratumumab and dexamethasone (SDd) therapy.

Journal: Frontiers in medicine

Published: December 31, 2023

CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy.

CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy.

Journal: Journal of Cancer

Published: December 26, 2023

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma.

A novel two-step administration of XPO-1 inhibitor may enhance the effect of anti-BCMA CAR-T in relapsed/refractory extramedullary multiple myeloma.

Journal: Journal of translational medicine

Published: August 27, 2023

Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma.

Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma.

Journal: Thrombosis research

Published: December 18, 2022

Mutations in immunodeficiency-related genes may increase the risk of infection after CAR-T-cell therapy: a report of two cases.

Mutations in immunodeficiency-related genes may increase the risk of infection after CAR-T-cell therapy: a report of two cases.

Journal: BMC infectious diseases

Published: November 06, 2022

The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.

The exploration of B cell maturation antigen expression in plasma cell dyscrasias beyond multiple myeloma.

Journal: BMC cancer

Published: October 15, 2022

Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.

Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report.

Journal: Journal for immunotherapy of cancer

Published: July 11, 2022

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.

Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.

Journal: Frontiers in immunology

Published: August 09, 2021

Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy.

Viral infection/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy.

Journal: Blood cancer journal

Published: June 29, 2021

Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.

Study on the Immune Escape Mechanism of Acute Myeloid Leukemia With DNMT3A Mutation.

Journal: Frontiers in immunology

Published: January 13, 2021

Showing 1-12 of 17

Last Updated: 09/26/2026